Japanese drugmaker Shionogi says it has submitted a marketing approval application for the digital therapeutic app SDT-001, for commercialization and sale in Japan. 27 February 2024
Privately-held UK biotech Curve Therapeutics today announced the closing of its successful £40.5 million ($51.4 million) Series A financing. 27 February 2024
Teva Pharmaceutical Industries has formed a partnership with Jiangsu Nhwa Pharmaceutical for the marketing and distribution in China of Teva’s Austedo (deutetrabenazine). 26 February 2024
Danish CNS specialist Lundbeck today announced a number of changes in its executive management team, first noting that Jacob Tolstrup, executive vice president, commercial operations, will leave the company no later than March 1, 2024. 23 February 2024
Shares of US clinical-stage biotech Coya Therapeutics leapt almost 10% to $8.82 in morning trading, after releasing a letter to stockholders from its chief executive and chairman, Dr Howard Berman. 21 February 2024
US biotech Denali Therapeutics saw its shares drop more than 8% to $16.66, after it revealed a setback for a partnered drug candidate in a stock exchange filing. 19 February 2024
Shares of Japanese drugmaker Otsuka Pharmaceutical fell more than 5% to 5,359 yen today, as it released top line results of the Phase III clinical trial of AVP-786 in the treatment of agitation associated with dementia due to Alzheimer's disease. 13 February 2024
The European Commission (EC) has authorized Biogen’s Skyclarys (omaveloxolone) for the treatment of Friedreich’s ataxia (FA) in adults and adolescents aged 16 years and older. 13 February 2024
Japan’s largest drugmaker Takeda Pharma has announced positive top-line results from a randomized, double-blind, placebo-controlled, multiple dose Phase IIb trial evaluating TAK-861, an oral orexin receptor 2 (OX2R) agonist, in patients with narcolepsy type 1. 9 February 2024
Germany-based Vivoryon Therapeutics could well be on the path towards altering the course of Alzheimer’s disease (AD), with a PhII data readout coming up and an option offering potential advantages over recently-approved monoclonal antibodies (mAbs). 9 February 2024
Regenerative cell therapy specialist Neurona Therapeutics has raised $120 million in a financing round co-led by Viking Global Investors and Cormorant Asset Management. 9 February 2024
French pharma major Sanofi has announced that Rippon Ubhi has been appointed as country lead for the UK and Ireland, taking over immediately from Jessamy Baird. 7 February 2024
CNS specialist Lundbeck has reported record annual revenue for 2023 of 19.91 billion Danish kroner ($2.87 billion), a 9% increase on 2022. 7 February 2024
Clinical-stage US biotech Acumen Pharmaceuticals has appointed James Doherty as president and chief development officer, effective February 1, 2024. 6 February 2024
Neuropsychologist Dr Paul Wicks joins the ranks of Cambridge, UK-based precision medicine scaleup Sano Genetics today, where he will take up the full-time role of vice president of neuroscience. 5 February 2024
US drugmaker AbbVie has finally faced its D-Day, having had to deal with declining revenues from its inflammatory diseases drug Humira (adalimumab) due to the first US competition to the mega blockbuster. 2 February 2024
A filing with the US Securities and Exchange Commission (SEC) reveals details of Kyverna Therapeutics’ bid to tap into an increasingly favorable market for initial public offerings (IPO). 2 February 2024
US clinical stage CNS drug developer Athira Pharma is taking decisive action following the company’s announcement of disappointing data from the Phase II/III LIFT-AD clinical trial of fosgonimeton to treat Alzheimer’s disease (AD). 18 September 2024
The US Food and Drug Administration (FDA) has approved Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq) for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS), from Swiss pharma giant Roche. 16 September 2024
US pharma major Eli Lilly has announced a $1 billion expansion of its manufacturing site in Limerick, Ireland, to increase production of biologic active ingredients, including those for its recently approved treatment for early symptomatic Alzheimer's disease. 13 September 2024
US neurological diseases specialist Ovid Therapeutics has announced the promotion of Meg Alexander to president and chief operating officer (COO). 12 September 2024
The global migraine market in mature economies is projected to grow from $9.2 billion in 2023 to $16.4 billion by 2033, according to a report from GlobalData. 10 September 2024
Cartesian Therapeutics today announced that the US Food and Drug Administration (FDA) has granted Rare Pediatric Disease designation to Descartes-08 for the treatment of juvenile dermatomyositis (JDM). 9 September 2024
California’s Lykos Therapeutics is still trying to regroup after being rocked by the US Food and Drug Administration’s (FDA) rejection of midomafetamine (MDMA) capsules for the treatment of post-traumatic stress disorder (PTSD). 6 September 2024
The cost of prescribed dependency-forming medicines has decreased by £410 million ($539.6 million) since 2015/16, according to newly released data from the UK’s National Health Service (NHS). 6 September 2024
Shares in US biopharma Axsome Therapeutics, a biopharmaceutical company developing and delivering novel therapies for the management of CNS disorders, closed 7% higher on Wednesday. 5 September 2024
Mid-Atlantic BioTherapeutics (MABT) has announced a collaboration with Accelero Biostructures to identify novel inhibitors of USP30, a protein linked to neurological disorders and other conditions. 5 September 2024
Praxis Precision Medicines shared positive top-line results for its Phase II, proof of concept study evaluating relutrigine in SCN2A and SCN8A developmental and epileptic encephalopathy (DEE) patients. 4 September 2024
Recursion (Nasdaq: RXRX) has seen its shares fall by more than 15% following the announcement of Phase II trial results for REC-994, an investigational treatment for symptomatic cerebral cavernous malformation (CCM). 4 September 2024
UK-based Amphista Therapeutics—which calls itself a leader in next generation targeted protein degradation (TPD) approaches—has named Antony Mattessich its new chief executive (CEO) and member of the board of directors. 3 September 2024
Japan’s Nxera Pharma today announced that it will receive a $35 million payment from Neurocrine Biosciences, triggered by the successful completion of the Phase II trial with NBI-1117568 (NBI-‘568) in adults with schizophrenia. 2 September 2024